Truly Labs AB is a CRO providing customized in vitro and in vivo services to its customers.

All work is characterized by our expertise, experience, commitment, flexibility and high quality standards.

Truly Labs was founded in January 2015 as a subsidiary of Truly Translational AB. The Truly Labs’ team has a solid track record with scientific and experimental expertise and experience from drug research & development in both large pharma and biotech. We have also extensive experience of working with both small molecules and biologics. Our key therapeutic areas are inflammation, respiratory diseases, oncology and autoimmune diseases where we offer state of the art in vitro and in vivo technologies.

As a member of the Medicon Valley Inhalation Consortium we also have access to unique competence and capabilities within inhalation, where Truly Labs offers preclinical in vivo inhalation pharmacology services.

MV_logo2_rgb

With offices at Medicon Village Science Park in Lund, Sweden, Truly Labs is centrally located in the buzzing Medicon Valley area. You can easily visit our facilities as Copenhagen and its international airport is only 30 minutes away.

OUR PEOPLE

Truly Labs AB was founded in early 2015 by former AstraZeneca employees with altogether more than 100 years experience from the Life Science sector, with an emphasis on bringing projects from in vitro studies and animal models into concept testing in patients. Our experiences span from pre-clinical research to early clinical drug discovery, pharmaceutical and biotech companies as well as both small molecules and biologicals. We have experience from project management, international environment and cross-functional teams. Our main expertise is in translational science and inflammatory diseases, and we have experiences from several therapeutic areas, including Respiratory, Oncology, Cardiovascular, Gastrointestinal and Autoimmunity.

COMPETENCE AREAS

The team at Truly Labs has many years of experience of designing, performing, and reporting high quality in vitro and in vivo studies in an efficient way. Our competence spans over several therapeutic areas as well as biopharmaceuticals and small molecules. We have a special interest in and can provide expertise and services within translational science and biomarkers. Biomarkers are becoming increasingly important in drug development and integrated with PK/PD data provide important links between preclinical and clinical development.

Our in vitro capabilities include in vitro pharmacology, cell biology, and biomarkers. The Truly Labs’ in vivo team has extensive expertise in generation of pharmacokinetic and pharmacodynamic data supporting the progression of drug projects. In addition, Truly Labs has unique competence of administration via inhalation.

Therapeutic Areas

  • Inflammation

  • Respiratory

  • Oncology

  • Cardiovascular

  • Autoimmunity

  • Gastointestinal

Experimental Areas

    In vitro Pharmacology

  • In vitro Pharmacology – Cell Based Assays

  • Biomarker analysis
  • In vivo Pharmacology

  • Pharmacokinetic (PK) studies

  • Customized pharmacodynamics (PD) models

  • PK/PD relationships and dose predictions

  • Administration routes and formulation

  • Inhalation

BOARD

Arne Bojesson

Senior Advisor at R & R Partners. Educated at Stockholm School of Economics in Business Administration and Economics. Experienced CFO and CEO from Medical device (Althin Medical) and Private Equity (Esalp Invest AB) business.

Charlott Brunmark

CSO and cofounder of Truly Labs AB and Truly Translational Sweden AB. Ph. D. In Medical Sciences from Lund University. Broad experience within In vivo pharmacology and pharmaceutical development of small molecules as well as biologics from Pharmacia Upjohn, Active Biotech, Cartela and AstraZeneca.

IngaLill Forslund Larsson

Partner at Lisberg Executive Search. Previously Marketing Director at AstraZeneca and Ferring Pharmaceuticals. Board member in life science companies, currently chairman of the board of XImmune AB, board member of LIDDS AB, and LU Bioscience AB.

Karin von Wachenfeldt

CEO and cofounder of Truly Labs AB and Truly Translational Sweden AB. Ph. D. In Immunotechnology from Lund University and Marketing Economist (EFL). Broad experience of early stage pharmaceutical development of small molecules and biopharmaceuticals from BioInvent, Pharmacia Upjohn, Active Biotech and AstraZeneca.

Per-Ola Önnervik

Principal Scientist and cofounder of Truly Labs AB. Extensive experience of the pharmaceutical industry with more than twenty years of drug discovery, in vivo pharmacology, and line management functions and thereafter management of clinical studies.